Amedisys (NASDAQ:AMED) had its price objective boosted by Robert W. Baird from $50.00 to $60.00 in a report published on Friday, November 10th. The firm currently has a neutral rating on the health services provider’s stock.
Several other research analysts also recently issued reports on the company. Craig Hallum reaffirmed a buy rating and set a $68.00 price objective (up previously from $55.00) on shares of Amedisys in a report on Thursday, November 9th. Royal Bank Of Canada reissued a sector perform rating and issued a $62.00 price target (up previously from $56.00) on shares of Amedisys in a research note on Thursday, November 9th. Benchmark reissued a hold rating on shares of Amedisys in a research note on Thursday, November 9th. Mizuho reissued a buy rating and issued a $65.00 price target (up previously from $55.00) on shares of Amedisys in a research note on Wednesday, November 8th. Finally, Jefferies Group restated a buy rating and issued a $60.00 price objective on shares of Amedisys in a research report on Thursday, October 12th. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $61.00.
Amedisys (NASDAQ AMED) traded up $1.51 during midday trading on Friday, reaching $54.06. The company had a trading volume of 544,400 shares, compared to its average volume of 327,793. The company has a market cap of $1,830.00, a price-to-earnings ratio of 26.85, a PEG ratio of 1.36 and a beta of 0.68. Amedisys has a 1-year low of $38.00 and a 1-year high of $65.91. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.33 and a current ratio of 1.33.
Hedge funds have recently added to or reduced their stakes in the business. Federated Investors Inc. PA grew its holdings in shares of Amedisys by 2.3% in the 2nd quarter. Federated Investors Inc. PA now owns 1,929 shares of the health services provider’s stock valued at $122,000 after acquiring an additional 44 shares in the last quarter. Riverhead Capital Management LLC grew its holdings in shares of Amedisys by 75.5% in the 2nd quarter. Riverhead Capital Management LLC now owns 1,931 shares of the health services provider’s stock valued at $121,000 after acquiring an additional 831 shares in the last quarter. CIBC Asset Management Inc bought a new position in shares of Amedisys in the 2nd quarter valued at about $230,000. Quantitative Systematic Strategies LLC bought a new position in shares of Amedisys in the 3rd quarter valued at about $205,000. Finally, SG Americas Securities LLC grew its holdings in shares of Amedisys by 48.7% in the 2nd quarter. SG Americas Securities LLC now owns 3,743 shares of the health services provider’s stock valued at $235,000 after acquiring an additional 1,226 shares in the last quarter. Hedge funds and other institutional investors own 94.37% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally published by BBNS and is the sole property of of BBNS. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://baseballnewssource.com/markets/amedisys-inc-amed-pt-raised-to-60-00/1775260.html.
Amedisys Company Profile
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with our FREE daily email newsletter.